Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,172
  • Shares Outstanding, K 46,497
  • Annual Sales, $ 140 K
  • Annual Income, $ -19,130 K
  • 60-Month Beta -0.60
  • Price/Sales 350.58
  • Price/Cash Flow N/A
  • Price/Book 0.84
Trade AIM with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.40
  • Most Recent Earnings -0.12 on 03/31/22
  • Next Earnings Date 05/17/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8301 +13.24%
on 05/18/22
1.1100 -15.32%
on 05/05/22
-0.1800 (-16.07%)
since 04/19/22
3-Month
0.5500 +70.91%
on 02/24/22
1.3800 -31.88%
on 04/11/22
+0.1506 (+19.08%)
since 02/18/22
52-Week
0.5500 +70.91%
on 02/24/22
2.4000 -60.83%
on 06/14/21
-1.1300 (-54.59%)
since 05/19/21

Most Recent Stories

More News
AIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update

- First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage...

AIM : 0.9400 (+5.44%)
AIM ImmunoTech to Participate in a Solve M.E. Signature Event: ‘Long COVID: Research, Policy, and Economic Impact’ on May 19, 2022

OCALA, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the...

AIM : 0.9400 (+5.44%)
AIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies

Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors ...

AIM : 0.9400 (+5.44%)
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

TBLT and SST are leading our pre-market stock movers for Tuesday

TBLT : 7.50 (-4.21%)
SIDU : 1.4900 (-0.67%)
AIM : 0.9400 (+5.44%)
STSS : 1.2300 (unch)
NAVB : 0.9000 (+9.76%)
AIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic Cancer

- Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with advanced...

AIM : 0.9400 (+5.44%)
AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen® as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment of Colorectal Cancer Metastatic to the Liver

Primary endpoint of the study was met, evidenced by increased CD8a expression post-treatment (p=0.046) Data suggest that CKM regimen with Ampligen may be...

AIM : 0.9400 (+5.44%)
AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer

Phase 1 study of metastatic triple-negative breast cancer using chemokine modulation (CKM) therapy, including Ampligen and pembrolizumab, successfully met...

AIM : 0.9400 (+5.44%)
AIM ImmunoTech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

- Year marked by continued execution across clinical development programs and the continued establishment of a growing body of positive data with Ampligen®...

AIM : 0.9400 (+5.44%)
AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World Congress

OCALA, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on...

AIM : 0.9400 (+5.44%)
AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Roswell

OCALA, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on...

AIM : 0.9400 (+5.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM...

See More

Key Turning Points

3rd Resistance Point 1.0733
2nd Resistance Point 1.0267
1st Resistance Point 0.9833
Last Price 0.9400
1st Support Level 0.8933
2nd Support Level 0.8467
3rd Support Level 0.8033

See More

52-Week High 2.4000
Fibonacci 61.8% 1.6933
Fibonacci 50% 1.4750
Fibonacci 38.2% 1.2567
Last Price 0.9400
52-Week Low 0.5500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar